Loading...
XNASCARM
Market cap18mUSD
Jan 17, Last price  
0.44USD
1D
-3.46%
1Q
-54.79%
Jan 2017
-97.65%
IPO
-99.60%
Name

Carisma Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:CARM chart
P/E
—
P/S
1.23
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
61.11%
Rev. gr., 5y
148.16%
Revenues
15m
+51.71%
001,334,0002,243,000990,00029,981,000425,0000011,236,00026,544,0009,834,00014,919,000
Net income
-87m
L+41.90%
-12,977,000-19,825,000-19,425,000-34,532,000-33,452,0001,891,000-29,029,000-33,693,000-107,500,000-28,320,000-40,774,000-61,226,000-86,879,000
CFO
-81m
L+972.92%
-10,869,000-19,092,000-13,494,000-29,307,000-34,529,0002,622,000-17,765,000-22,829,000-37,521,000-27,012,000-37,328,000-7,566,000-81,177,000
Dividend
Mar 08, 20230.0181 USD/sh
Earnings
May 07, 2025

Profile

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
URL
https://sesenbio.com/
IPO date
Feb 06, 2014
Employees
17
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
14,919
51.71%
9,834
-62.95%
Cost of revenue
177,775
102,495
Unusual Expense (Income)
NOPBT
(162,856)
(92,661)
NOPBT Margin
Operating Taxes
(3,875)
Tax Rate
NOPAT
(162,856)
(88,786)
Net income
(86,879)
41.90%
(61,226)
50.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
31,237
35,106
BB yield
-31.80%
-5,753.00%
Debt
Debt current
3,870
4,599
Long-term debt
4,311
35,565
Deferred revenue
45,000
45,000
Other long-term liabilities
926
(79,564)
Net debt
(69,424)
(11,862)
Cash flow
Cash from operating activities
(81,177)
(7,566)
CAPEX
(1,132)
(4,660)
Cash from investing activities
72,408
(32,560)
Cash from financing activities
62,180
35,769
FCF
(158,343)
(96,573)
Balance
Cash
77,605
51,996
Long term investments
30
Excess cash
76,859
51,534
Stockholders' equity
(245,062)
(36,059)
Invested Capital
322,578
10,688
ROIC
287.89%
ROCE
EV
Common stock shares outstanding
33,524
106
Price
2.93
-48.91%
5.74
-26.38%
Market cap
98,226
15,996.77%
610
-99.14%
EV
28,802
110,951
EBITDA
(160,019)
(86,571)
EV/EBITDA
Interest
3,145
Interest/NOPBT